BSX — Boston Scientific Corporation

The market is repricing BSX's growth story, not just a bad quarter. Management cut FY2026 organic sales guidance twice - now 5-6%, down from initial 10-11% - and guided Q3 to only 3-5% growth, citing WATCHMAN demand deceleration and U.S. electrophysiology share loss. Despite a Q2 adjusted EPS beat, the stock fell sharply and is down ~50% YTD.

Revenue growth has decelerated steadily from ~20-23% YoY through 2024 and early 2025 to 15.9% in Q4 2025, 11.6% in Q1 2026, and 7.5% in Q2 2026 (7.0% organic). This is structural, not a one-off blip: management's own FY guidance implies 5-6% organic growth, and Q3 guidance is 3-5%. On the profitability side, operating margin expanded from 16.2% in Q2 2025 to 21.6% in Q2 2026, and TTM gross margin is 71.2%, so the company is growing slower but earning more per dollar of revenue. Q1 2026 net income (EPS $0.90) includes one-off items; TTM GAAP EPS is $2.48 while forward adjusted EPS is ~$3.30.

Cheap versus its own history on most metrics: TTM P/E is 18.8x vs. a 5-year average of 67.5x, P/S is 3.3x vs. 6.2x average, and PEG is 0.41. On forward adjusted EPS of ~$3.30, the stock trades at only ~14.1x - a de-rated multiple. The caveat is that consensus EPS still assumes continued margin/buyback support; if organic growth falls below 3-5%, those estimates will be cut, so the cheap multiple is not automatically a bargain.

At $46.67, the price is discounting continued deceleration and perhaps additional WATCHMAN/EP market share loss, not the old 10%+ growth story. The earnings play is asymmetric in favor of stabilization: if Q3 meets the low 3-5% guide and EPS guidance holds at $3.28-3.32, the current 14x forward multiple should re-rate toward the mid-to-high teens. If Q3 comes in below the range or guidance is cut a third time, forward EPS will fall and the stock can stay cheap or go cheaper.

As of 2026-08-27, RSI was 42.25 - weak but not oversold - and price was 6.15% below the 20-day SMA, roughly flat versus the 50-day (+0.29%), and 31.78% below the 200-day SMA. That is a confirmed long-term downtrend with no reversal signal yet. Tactically, the risk/reward improves only after BSX reclaims the 20-day and 50-day moving averages and RSI climbs above 50; buying here is catching a falling knife.

• MedTech sector de-rating: the IHI medical devices ETF is down double-digits over the past year as hospital capital budgets tightened and post-pandemic procedure comps normalized.
• Elevated interest rates raise the cost of capital for large M&A such as Penumbra and the MiRus investment, making organic margin expansion more important.
• Hyper-competitive electrophysiology and structural heart markets: rivals are moving fast in PFA and LAA closure, forcing BSX into share-defense spending.
• Clinical/regulatory scrutiny of device data (e.g., nuanced WATCHMAN CHAMPION-AF readout) can shift physician referral patterns and procedure volumes.
• A slower procedure-growth environment in the U.S. creates a tough backdrop for the 5-6% organic guidance to be beaten.

• Q3 2026 earnings (late October 2026): a print within or above the 3-5% organic guide would be the first evidence the deceleration is stabilizing.
• Wells Fargo Healthcare Conference: management credibility on second-half trajectory and WATCHMAN/EP commentary will move the stock near-term.
• Closing and integration of the Penumbra acquisition and MiRus TAVR progress could restore the M&A-driven growth narrative.
• International adoption of FARAPULSE and coronary lithotripsy milestones remain bright spots that could re-accelerate top-line growth.

• WATCHMAN demand deceleration deepens due to competitive LAA closure devices and clinical-data-driven referral shifts.
• U.S. electrophysiology share loss accelerates, particularly in PFA, squeezing the two largest growth pillars.
• Q3 organic growth misses the 3-5% guide, triggering a third cut and further downward estimate revisions.
• Large pending M&A (Penumbra, MiRus) increases integration risk, leverage, and execution complexity.
• A sustained high-rate environment keeps medtech multiples compressed and makes capital deployment more dilutive.

Boston Scientific is a high-quality medical-device franchise with expanding margins, strong free cash flow (~$3.6B TTM), and a clean balance sheet, but its two biggest growth engines - WATCHMAN and U.S. EP - are faltering and management has already cut guidance twice. At $46.67 the stock is pricing in a real slowdown, so the downside is less scary than it was at $100; however, there is no evidence yet of stabilization. This is a watchlist candidate rather than an aggressive buy until Q3 confirms the growth floor.

Fair value estimated by applying a 17.5x justified forward P/E to FY2026 adjusted EPS of ~$3.30. The multiple is a discount to BSX's 5-year average and to its historical premium-growth valuation, reflecting decelerated 5-6% organic growth and EP/WATCHMAN competitive pressure, but it is above the current ~14.1x forward multiple because profitability, FCF, and earnings quality remain strong.